According to a new PALLAS research, palbociclib did not increase metastatic disease-free survival when added to adjuvant endocrine therapy for individuals with early-stage HR+/HER2-breast cancer as compared with adjuvant endocrine therapy alone. This evidence concerns the gene ERBB2 and breast cancer.